Cordis Corp., a Johnson & Johnson (NYSE:JNJ) subsidiary, said it inked an exclusive deal to distribute TriReme Medical’s Chocolate PTA balloon catheter.
The Chocolate PTA device is designed to treat peripheral artery disease
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
By Chris Walker
Cordis Corp., a Johnson & Johnson (NYSE:JNJ) subsidiary, said it inked an exclusive deal to distribute TriReme Medical’s Chocolate PTA balloon catheter.
The Chocolate PTA device is designed to treat peripheral artery disease
Cordis Corp, a Johnson & Johnson (NYSE:JNJ) subsidiary, released 2-year data from its INNOVATION trial testing the safety and performance of the Incraft abdominal aortic aneurysm stent graft system.
Johnson & Johnson‘s (NYSE:JNJ) Cordis stent-making arm won the final round in a patent infringement battle with stent pioneer Dr. Bruce Saffran when the U.S. Supreme Court yesterday declined to hear Saffran’s appeal.
Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. reported another year of results from its STROLL trial, which studied the durability and performance of the company’s S.M.A.R.T. vascular stent.
A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.
Stent pioneer Dr. Bruce Saffran asked the U.S. Supreme Court to hear an appeal of a lower court’s decision to overturn his $593 million win in a patent infringement lawsuit against Johnson & Johnson‘s (NYSE:JNJ) Cordis stent-making arm.
Cordis Corp., the stent-making arm of Johnson & Johnson (NYSE:JNJ), got out of the coronary stent game 2 years ago, but that’s not stopping Israeli medical device company Medinol from suing Cordis for patent infringement with the Cypher and Cypher Select stents it no longer makes.
Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.
The recall last March of Johnson & Johnson (NYSE:JNJ) unit Cordis Corp.’s Optease vena cava filter is Class I, according to the FDA, meaning the device could cause serious injury or death.